TRMED — Thor Medical ASA Share Price
Last trade - 00:00- NOK252.22m
- NOK210.46m
- 11
- 48
- 42
- 23
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.93 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -2.19% | ||
| Return on Equity | -3.31% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NOKm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
Directors
- Jan Egberts NEC (62)
- Erik Skullerud CEO
- Malene Brondberg CFO (48)
- Sandra Jonsson COO
- Lars Nieba CTO (53)
- Jostein Dahle CSO (48)
- Gabriele Elbl VPR (59)
- Rosemarie Corrigan OTH (56)
- Pierre Dodion OTH (64)
- Per Samuelsson DRC (60)
- Jean-Pierre Bizzari IND (66)
- Rainer Boehm IND (60)
- Joanna Horobin IND (66)
- Karin Meyer IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 7th, 2009
- Public Since
- July 7th, 2014
- No. of Shareholders
- 10,950
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Oslo Stock Exchange
- Shares in Issue
- 233,539,006
- Address
- Kjelsasveien 168 B, OSLO, 0884
- Web
- https://www.nordicnanovector.com/
- Phone
- +47 22183301
- Auditors
- Ernst & Young AS
Upcoming Events for TRMED
Similar to TRMED
Arcticzymes Technologies ASA
Oslo Stock Exchange
Bergenbio ASA
Oslo Stock Exchange
Circio Holding ASA
Oslo Stock Exchange
Exact Therapeutics AS
Oslo Stock Exchange
Lifecare AS
Oslo Stock Exchange
FAQ
As of Today at 19:21 UTC, shares in Thor Medical ASA are trading at NOK1.08. This share price information is delayed by 15 minutes.
Shares in Thor Medical ASA last closed at NOK1.08 and the price had moved by +36.88% over the past 365 days. In terms of relative price strength the Thor Medical ASA share price has outperformed the FTSE Global All Cap Index by +25.4% over the past year.
The overall consensus recommendation for Thor Medical ASA is Strong Sell. You can view the full broker recommendation list by unlocking its StockReport.
Thor Medical ASA does not currently pay a dividend.
Thor Medical ASA does not currently pay a dividend.
Thor Medical ASA does not currently pay a dividend.
To buy shares in Thor Medical ASA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of NOK1.08, shares in Thor Medical ASA had a market capitalisation of NOK252.22m.
Here are the trading details for Thor Medical ASA:
- Country of listing: Norway
- Exchange: OSL
- Ticker Symbol: TRMED
Based on an overall assessment of its quality, value and momentum Thor Medical ASA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Thor Medical ASA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -26.35%.
As of the last closing price of NOK1.08, shares in Thor Medical ASA were trading -13.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Thor Medical ASA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at NOK1.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Thor Medical ASA's management team is headed by:
- Jan Egberts - NEC
- Erik Skullerud - CEO
- Malene Brondberg - CFO
- Sandra Jonsson - COO
- Lars Nieba - CTO
- Jostein Dahle - CSO
- Gabriele Elbl - VPR
- Rosemarie Corrigan - OTH
- Pierre Dodion - OTH
- Per Samuelsson - DRC
- Jean-Pierre Bizzari - IND
- Rainer Boehm - IND
- Joanna Horobin - IND
- Karin Meyer - IND